Research Paper Volume 12, Issue 15 pp 15656—15669
CTLA-4 immunotherapy exposes differences in immune response along with different tumor progression in colorectal cancer
Figure 2. Ki-67 immunohistochemistry analysis of the proliferation of the tumor tissue in the difference groups. Ki-67 staining in the vehicle group (A), the 200 mm3 group (B), the 400 mm3 group (C), and the 800 mm3 group (D); n = 5 mice per group. Data are statistically significant for anti-CTLA-4 antibody 10 mg/kg intraperitoneal injection weekly; **, P < 0.01 on day17, Photos of the tumors isolated from mice inoculated with the CT26 cells. For group 2 (start treatment with the tumor size of 100mm3), no IHC staining is shown due to the small tumor volume on the final day.